Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems
Highlights
► rHA produced and purified by various means are tested as reagents in immune assays. ► rHA produced and purified by various means are tested as immunogens in mice. ► rHA production process impacts the protein's antigenicity in immune assays. ► rHA proteins elicit relevant HAI responses independent of the production process. ► rHA oligomerization correlate with its antigenic and immunogenic properties.
Introduction
Influenza hemagglutinin (HA) glycoproteins are responsible for two major events in the influenza life cycle: (a) binding/attachment to sialic acid containing receptors in the target cells and (b) the fusion of the virus membrane with the endosomal membrane resulting in the release of the viral genome into the cytosol of the target cell [1], [2]. Due to the role of the HA in key aspects of the virus life cycle, and its relative abundance in the surface of the viral membrane, this protein is a relevant target for the humoral response. Indeed, a substantial portion of the antibody response following influenza infection in mice and humans is directed against the HA, with a population of these antibodies capable of neutralizing HA binding and/or fusion [3], [4], [5], [6], [7], [8]. More importantly, these antibodies are sufficient for protection against live virus infection [3], [9], [10], [11], [12] and their concentration shows a negative correlation with disease incidence in humans [12], [13], [14].
In the United States, current FDA licensed influenza vaccines have been optimized to maximize the generation of B cell and antibody responses against the HA of the strains included in the vaccine. In addition, a number of experimental vaccines, are also focused on eliciting antibody responses to the HA component of the vaccine (DNA, recombinant HA, and virus-like particles) [15], [16], [17], [18], [19], [20], [21]. Recombinant HA (rHA) proteins have been widely used to study B cell responses following vaccination and/or infection in humans and animals alike [21], [22], [23]. These proteins have been produce in an assortment of protein expression systems including yeast, bacteria, insect cells, plant cells, and human cell lines [24], [25], [26], [27], [28], [29], [30]. However, to appropriately measure responses to the HA protein of interest it is imperative that the rHA that most resembles the viral HA is chosen. In addition, there are recent efforts to license baculovirus-derived rHA vaccines for seasonal and pandemic strains of influenza [25], [31], [32]. However, while these vaccines have been shown to elicit comparable responses to conventional influenza vaccines, no systematic study of these different forms of the HA protein have been conducted. It is not clear which, if any, of these different protein expression systems improve or diminish the biological behavior of the proteins as viewed by the immune system. Therefore we set out to perform systematic evaluation of rHA produced in different protein expression systems. Five rHA proteins based on recent strains of seasonal influenza A and five based on influenza B HA were obtained through the Biodefense and Emerging Infections Research Resources Repository (BEIR). These proteins were evaluated in a combination of biochemical and structural assays, in vitro humoral and cellular immune assays, and in an animal vaccination model. Marked differences in the behavior of the individual proteins were evident suggesting that they are not equal in being used to detect or elicit an immune response.
Section snippets
Recombinant HA proteins
Purified rHAs from A/Brisbane/59/07 and B/Florida/04/06 listed below (and Table 1) were obtained through the NIH BEIR Repository (NIH/NIAID). For influenza A/Brisbane/59/07: truncated H1 HA protein with a C-terminal trimerization (T4 fibritin foldon) domain, thrombin cut site, and histidine tag produced in Trichoplusia ni High Five insect cells (Tni), NR-15476; truncated H1 HA protein with C-terminal histidine tag produced in human 293 cells (HEK), NR-15477; full-length H1 HA protein produced
Physical properties of recombinant influenza HA proteins
HA purified from the surface of influenza virions aggregates into structures containing 6–8 HA trimers [38]. However, expressed rHA proteins can be observed as oligomers, trimers, and/or monomers [16], [39]. In order to determine the predominant form of the rHA in these preparations we performed size exclusion chromatography. Protein preparations derived from Sf9 cells were primarily composed of high molecular weight oligomers (HMWO) (Fig. 1C, E, H, and J). These oligomers display molecular
Discussion
Long lasting immunity to influenza, whether it is induced by infection or vaccination, depends on the ability of the humoral arm of the immune system to respond to the virus HA protein. Indeed, a substantial portion of the antibody response following influenza infection in mice and humans is directed against the HA. Because of this, understanding the responses against the HA is one of the main focuses of influenza research. Recombinant versions of influenza HAs are widely available as reagents
Acknowledgements
This work was supported by the New York Influenza Center of Excellence, part of the NIH/NIAID network of Centers of Excellence in Influenza Research and Surveillance (CEIRS), contract #HHS-N266200700008C. The rHA reagents used to conduct this research were kindly provided by the Biodefense and Emerging Infections Research Resources Repository.
References (67)
- et al.
Immunogenicity and protective efficacy of influenza vaccination
Virus Research
(2004) - et al.
An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults
Vaccine
(2011) - et al.
B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant
Vaccine
(2010) - et al.
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus
Vaccine
(2009) - et al.
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months
Vaccine
(2009) - et al.
Expression and purification of an influenza hemagglutinin – one step closer to a recombinant protein-based influenza vaccine
Vaccine
(2006) - et al.
Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines
Vaccine
(2011) Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae
Biochimica et Biophysica Acta
(1957)- et al.
Virus glycosylation: role in virulence and immune interactions
Trends in microbiology
(2007) - et al.
The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity
Virology
(2010)
Studies of influenza haemagglutinin-mediated membrane fusion
Virology
Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity
Cell
Dual expression of the HA protein of H5N2 avian influenza virus in a baculovirus system
Journal of Virological Methods
Exposure of hydrophobic surfaces initiates aggregation of diverse ALS-causing superoxide dismutase-1 mutants
Journal of Molecular Biology
The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity
Virology
Glycosylation of the hemagglutinin modulates the sensitivity of H3N2 influenza viruses to innate proteins in airway secretions and virulence in mice
Virology
Vaccine design of hemagglutinin glycoprotein against influenza
Trends in Biotechnology
Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells
Vaccine
The role of influenza virus haemagglutinin in membrane fusion
Microbiological Sciences
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin
Annual Review of Biochemistry
Determinants of immunity to influenza infection in man
British Medical Bulletin
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
Journal of Experimental Medicine
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM + memory B cells
PLoS One
Lack of identity in neutralizing and hemagglutination-inhibiting antibodies against influenza viruses
Journal of Experimental Medicine
Influenza virus vaccine based on the conserved hemagglutinin stalk domain
MBio
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine
Journal of Clinical Investigation
The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
Journal of Hygiene
Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin
PLoS One
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza
PLoS Med
Protection of infants from infection with influenza-A virus by transplacentally acquired antibody
Journal of Infectious Diseases
Immune correlates of protection against influenza in the human challenge model
Developmental Biology (Basel)
Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria
Journal of Medical Virology
Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus
Journal of Virology
Cited by (18)
Identification of the dominant non-neutralizing epitope in the haemagglutinin of H7N9 avian influenza virus
2021, Virus ResearchCitation Excerpt :The HA proteins expressed in sf9 insect cells are rich in N-glycans with paucimannosidic and oligomannosidic structures, whereas those derived from eggs are rich in high mannose and complex N-glycans (An et al., 2019, 2013; Krammer and Grabherr, 2010). Santiago et al. reported that the HA proteins produced in different expression systems differed markedly in the behavior when being used to detect an immune response to influenza vaccines, with significantly higher IgG titers against HAs expressed in sf9 cells (Santiago et al., 2012). Therefore, it is speculated that the coating H7 HA produced in BES may have a robust binding affinity with the competing mAb, which may further reduce HA-binding of H7N9 antisera.
Opportunities and challenges of the tag-assisted protein purification techniques: Applications in the pharmaceutical industry
2020, Biotechnology AdvancesCitation Excerpt :They can also improve the production yield and quality of the expression systems. Functional tags can facilitate the proper folding of the desired protein (Paraskevopoulou and Falcone, 2018), prevent the proteolysis (Kimple et al., 2013), inhibit the antigenicity of the fusion protein (Jin et al., 2017a; Santiago et al., 2012), improve their functional properties (Zhao and Huang, 2016), and increase the solubility of the target protein (Mayer et al., 2004). Peptide and protein tags that help to enhance the solubility of their associated target proteins are known as solubility enhancer peptides/proteins (SEPs) and can be used for a variety of purposes (Paraskevopoulou and Falcone, 2018).
Enhanced cross-lineage protection induced by recombinant H9N2 avian influenza virus inactivated vaccine
2019, VaccineCitation Excerpt :Some studies revealed that most neutralizing antibodies responded directly against the HA, which were capable of neutralizing HA binding and/or fusion. More importantly, neutralizing antibodies were sufficient for protection against live virus infection and their concentration showed a negative correlation with disease incidence [33]. Therefore, rSNHA-△200 induced significantly higher neutralizing antibodies and the best protection against both homologous and heterologous H9N2 AIVs, and could be used as a cross-protection vaccine candidate to control and prevent H9N2 AIV infections.
Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines
2015, Virus ResearchCitation Excerpt :A titer of 5 was assigned when negative HI reactions occurred at ≥1:10. Influenza-specific IgG ELISA was performed as described (Santiago et al., 2012). In brief, 96-well flat-bottom plates were coated with 0.5 ng of HA of influenza reference antigens (NIBSC, UK) overnight at 4 °C, followed by blocking with 1% BSA/PBS for 1 h at 37 °C.
Mechanism of a decrease in potency for the recombinant influenza a virus hemagglutinin H3 antigen during storage
2014, Journal of Pharmaceutical SciencesCitation Excerpt :During production of the recombinant protein in a host cell, these Cys residues are expected to be reduced, but purification and formulation/storage of the hemagglutinin proteins could potentially allow these residues to oxidize, resulting in formation of non-native disulfide bonds. In addition, the native oligomeric states of rHA (homotrimer and rosette)13 could also exacerbate the formation of non-native disulfide bonds through close proximity of the many Cys residues in these higher ordered structures. The slower loss in potency observed in rHA treated with TX supports this idea, since the detergent likely limited the proximity of the rHA in the higher ordered structures and, therefore, decreased the number of non-native disulfide bonds.
Expression and purification of bioactive hemagglutinin protein of highly pathogenic avian influenza A (H5N1) in silkworm larvae
2013, Journal of Virological MethodsCitation Excerpt :These results indicate that rHAs form oligomers with a molecular weight bigger than 669 kDa. In a previous report (Santiago et al., 2012), HA from influenza virus A/Brisbane/59/70 expressed in Sf-9 cells mainly formed high molecular weight oligomers, and was suggested to be composed of at least 3 HA trimers. Results of size exclusion chromatography in this study corresponded to results in a previous report.